Expedited pathway portfolios, trial complexity, and FDA approval timelines in oncology and neurology: A comparative analysis.
FDA expedited programs are intended to facilitate development and review for therapies addressing serious conditions with unmet medical need, but their use may depend on whether the evidentiary package is compatible with regulatory acceleration. We compared FDA original approvals in oncology and neurology from 2015 to 2024 to evaluate whether differences in approval timing reflected expedited pathway portfolio intensity, pivotal evidence architecture, or alignment between the two.
FDA expedited programs are intended to facilitate development and review for therapies addressing serious conditions with unmet medical need, but their use may depend on whether the evidentiary package is compatible with regulatory acceleration. We compared FDA original approvals in oncology and neurology from 2015 to 2024 to evaluate whether differences in approval timing reflected expedited pathway portfolio intensity, pivotal evidence architecture, or alignment between the two.
What the study was
- Study design
- Validation/Comparative Study
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- PLoS One
Why it surfaced
Matched watchlist topic 'Rare diseases with high unmet need'. Study design: Validation/Comparative Study. Score: 10/10 (N:3, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.